Analysts expect that Alimera Sciences Inc (NASDAQ:ALIM) will announce $5.14 million in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Alimera Sciences’ earnings. The highest sales estimate is $8.02 million and the lowest is $2.25 million. Alimera Sciences reported sales of $10.86 million in the same quarter last year, which indicates a negative year-over-year growth rate of 52.7%. The firm is scheduled to announce its next earnings results on Monday, August 3rd.
On average, analysts expect that Alimera Sciences will report full year sales of $50.07 million for the current financial year, with estimates ranging from $48.29 million to $51.84 million. For the next fiscal year, analysts forecast that the company will report sales of $63.16 million, with estimates ranging from $60.05 million to $66.26 million. Zacks’ sales calculations are an average based on a survey of analysts that follow Alimera Sciences.
Alimera Sciences (NASDAQ:ALIM) last posted its earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.19. The company had revenue of $14.54 million during the quarter, compared to the consensus estimate of $14.04 million.
Shares of NASDAQ ALIM traded down $0.10 during midday trading on Friday, reaching $6.39. 57,791 shares of the company traded hands, compared to its average volume of 42,449. Alimera Sciences has a 52 week low of $2.86 and a 52 week high of $14.82. The stock has a 50-day moving average price of $5.45 and a 200 day moving average price of $5.91. The company has a market cap of $32.15 million, a price-to-earnings ratio of -3.53 and a beta of 2.20.
About Alimera Sciences
Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.
Recommended Story: Why Invest in High-Yield Dividend Stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.